Alzheimer Disease

U.S. FDA approves IND from Siemens for clinical study of Alzheimer-specific imaging agent

Published in Medical Device Business Week, January 24th, 2007

Siemens Medical Solutions announced that it will begin clinical trials under an investigational new drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for a breakthrough imaging biomarker that could potentially identify Alzheimer disease prior to the onset of noticeable symptoms.

Siemens will collaborate with Alzheimer researchers at the University of California, Los Angeles (UCLA) to launch a phase 1, open label, single center safety study of one of the first imaging biomarkers designed to identify Alzheimer disease pathology specifically. The study will employ a new diagnostic technique developed by UCLA researchers that combines the new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2007-01-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry